Ipamorelin selectively targets GHS-R1a, promoting GH release via calcium-mediated pathways 1-5
Consultation with the FDA resulted in a reduction in the studys sample size from 600 to 292 patients based on the measured pooled incidence of the primary endpoint and a re-estimation of the study power
Yohimbe/Yohimbine Some evidence exists, but side effects can be serious: anxiety, increased heart rate, high blood pressure, panic symptoms, and medication interactions
Doi: Lee JE, Jang H, Cho EJ, Youn HD (2009) Down Syndrome Critical Region 1 Enhances the Proteolytic Cleavage of Calcineurin
Unusual odor: The solution should have little to no odor
Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)